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Abstract Treatment options for ADHD in the Nether-
lands have increased with the introduction of the extended-
release formulations of methylphenidate (MPH ER,
Concerta
) in 2003 and atomoxetine (ATX, Strattera
)i n
2005, but data on the effect on drug usage patterns are
scarce. The objective of the present study was to describe
changes in the patterns of ADHD medication use and
determinants thereof among children, adolescents and
adults (\45 years) starting ADHD medication since the
introduction of MPH ER and ATX. Data were obtained
from Dutch community pharmacies as collected by the
Foundation for Pharmaceutical Statistics, covering 97% of
all dispenses for prescription medicines to outpatients in
the Netherlands. Usage patterns (continuation, discontinu-
ation, switching and addition) of ADHD drugs were eval-
uated at 3, 6 and 12 months after initiation for three
separate time cohorts (patients starting ADHD medication
in Jan-Dec 2002, Jan 2003–June 2004, respectively July
2004–Dec 2005). It was found that between 2002 and 2006,
most ADHD drug users were initiated on methylphenidate
IR. Discontinuation of any ADHD drug treatment
decreased over time partly in favour of switching and
addition. Discontinuation at 3 months decreased from
around 33% to around 25%, at 6 months from less than
50% to almost 35%, and at 12 months from just fewer than
60% to less than 45%. Discontinuation was higher among
females and in adults[18 years. After the introduction of
MPH ER and ATX (time cohort III), 16.5% of the incident
ADHD drug users switched their medication and almost
9% added an ADHD drug to the prior ADHD drug. In
conclusion, discontinuation of incident ADHD drug use is
high after 3, 6 and 12 months. During the study period, the
incidence of discontinuation decreased because of the
availability of extended-release methylphenidate and
atomoxetine.
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Attention Deﬁcit Hyperactivity Disorder (ADHD) is a
neurobiological psychiatric disorder that occurs in child-
hood, adolescence and adulthood. The prevalence of
ADHD has been estimated at 3.0–7.5% among youth
(Buitelaar 2002) and between 1.0 and 4.7% among adults
(Ten Have et al. 2006; Murphy and Barkley 1996; Kessler
et al. 2005; de Ridder et al. 2008). Many patients are not
outgrowing their ADHD, indicating that it is a lifetime
disorder requiring chronic treatment (Faraone et al. 2006).
Psychopharmacological treatment is one of the most
effective currently available treatment options in ADHD
(Practice Parameter for the use of stimulant medications in
the treatment of children, adolescents and adults 2002;
Multidisciplinaire Richtlijn ADHD 2005). During the last
decade, the pharmacotherapeutic options for the treatment
of ADHD in the Netherlands have widened by the intro-
duction of extended-release formulations of methylpheni-
date (MPH ER, Concerta
) in 2003 and the new active
molecule atomoxetine (ATX, Strattera
) in 2005. Before
2003, only methylphenidate immediate release (MPH IR,
Ritalin
) was approved in the Netherlands for the treat-
ment of patients 6–18 years old with ADHD, while dex-
amphetamine (Dexedrin
), nortryptilin (Nortrilen
) and
clonidine (Dixarit
) were used off-label for this indication.
Studies in several countries, including The Netherlands,
have shown a strong increase during the last two decades in
prevalence and incidence in the use of ADHD medication
among preschoolers, children and adults (Robison et al.
1999, 2005; Zito et al. 2000, 2007, 2008; Miller et al. 2001;
Schirm et al. 2001; Reid et al. 2002; DeBar et al. 2003;
Hugtenburg et al. 2005; DosReis et al. 2005; Faber et al.
2005; Vinker et al. 2006; Castle et al. 2007; Winterstein
et al. 2008; Mitchell et al. 2008; Trip et al. 2009; van den
Ban et al. 2010). US data have suggested that the average
duration of psychostimulant use ranges from 5 years for
middle school students (Safer and Krager 1994; Angold
et al. 2000) to 8 years for high school students. Dutch
studies have shown a shift towards longer duration of use
from 1995 to 2006 (Schirm et al. 2001; Faber et al. 2005;
Trip et al. 2009). Incidences and usage patterns differ
between countries and within countries because there are
differences regarding use of diagnostic classiﬁcation sys-
tems, practice guidelines, cultural beliefs about use of
medication, reimbursement possibilities, government regu-
lations and drug advertising (Schefﬂer et al. 2007; Mitchell
et al. 2008; Vitiello 2008; Zito 2008). However, little is
known how treatment patterns like continuation or discon-
tinuation, switching and combining ADHD drugs have
changed after the introduction of the newer ADHD drugs.
The objective of this study was to assess changes in
ADHD medication usage patterns (continuation,
discontinuation, switching and addition) and determinants
thereof in children, adolescents and adults \45 years ini-
tiated on ADHD drugs in the Netherlands since the avail-
ability of the long-acting ADHD drugs MPH ER and ATX.
Methods
Setting and study population
Drug-dispensing data for this study were obtained from the
Foundation for Pharmaceutical Statistics (Stichting Far-
maceutische Kengetallen, SFK). As of 1990, SFK has been
collecting dispensing data from a growing number of
community pharmacies in the Netherlands. In 2001, the
catchment area of SFK comprised 1,629 community phar-
macies in both rural and urban areas all over the Nether-
lands, representing 90.7% of the total number of Dutch
pharmacies. In 2006, coverage had increased to 92% of the
total number of Dutch pharmacies and 97% of the Dutch
population (http://www.sfk.nl). For this study, we used data
from those 745 pharmacies with a complete medication
history of the patients from 2001 to 2006. As the majority of
patients in the Netherlands designate a single pharmacy to
ﬁll prescriptions from general practitioners or medical
specialists, dispensing histories provide an almost complete
account of prescription drug exposure in time (Buurma et al.
2008). Information about the prescribed medication con-
tained patient data (anonymous ID, gender, year of birth),
dispensing date, number of units dispensed and prescribed
daily dose. From the SFK database, all patients born after
1960 (i.e.\45 years of age) were identiﬁed with at least one
prescription dispensed between January 2002 and Decem-
ber 2005 for a drug approved for the treatment of ADHD
(methylphenidate IR and ER, atomoxetine). From here on,
these drugs will be referred to as ‘ADHD drugs’. The date
of the ﬁrst dispensing of an ADHD drug marked the start of
follow-up. Only incident users of an ADHD drug were
included in this study, where an incident user was deﬁned as
a patient having no ADHD drug dispensed during the
12 months prior. All patients were therefore required to
have at least 12 months of history in the SFK database prior
to this prescription date and also 12 months of follow-up
after cohort-entry in order to be able to evaluate medication
usage patterns. Three time cohorts were deﬁned according
to the year of ADHD drug initiation: I: January 2002–
December 2002, II: January 2003–June 2004 and III: July
2004–December 2005.
ADHD drug usage patterns
For each included patient, all prescriptions for ADHD
drugs were identiﬁed. The theoretical duration of use of
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123each prescription was calculated by using information
about the dispensing date, the number of units dispensed
and the prescribed dosage regimen. For each subsequent
dispensed prescription for an ADHD drug, the drug usage
pattern was classiﬁed as continuation, discontinuation,
switching or addition. Continuation was deﬁned as
continuing the initially prescribed ADHD drug. Discon-
tinuation of ADHD treatment was deﬁned as not having
reﬁlled a new prescription for any ADHD drug within
3 months after the theoretical end date of the previous
prescription. Switching was deﬁned as changing from one
type of ADHD drug to another. Addition was deﬁned as
starting another type of ADHD drug while continuing the
initially prescribed drug.
Data analysis
Demographic characteristics at baseline were compared
between the three time cohorts. Age was categorized in
four age strata: 0–5, 6–11, 12–17 and 18–45 years.
Patients were followed up from cohort-entry to the ﬁrst
change in ADHD treatment (discontinuation, switch,
addition,) or censoring, whichever came ﬁrst. The fre-
quency of study outcomes for each time cohort was
assessed at 3, 6 and 12 months after cohort-entry. Cox
regression analysis was conducted to assess the strength of
the association between determinants and discontinuation
and was expressed as a hazard ratio (HR) with 95% con-
ﬁdence interval (CI). The association between determinants
(gender, age, initial ADHD drug) and switching and
addition was studied for time cohort III only, because by
that time both MPH ER formulations as well as atomoxe-
tine were available on the Dutch market.
Results
We identiﬁed 62,098 unique patients and our study popu-
lation comprised 13,489 incident users of ADHD drugs
(Table 1). Overall, 72.6% were male and 44.2% were aged
between 6 and 11 years of age. There were no major dif-
ferences in the male/female ratio and age distribution
between the three time cohorts. The absolute number of
patients initiating ADHD drug treatment increased over
time. The vast majority of patients (93.7%) were initiated
on methylphenidate IR.
Figure 1 shows the proportion of patients having one of
the medication usage pattern events at 3, 6 and 12 months
for the three time cohorts. The number of patients contin-
uing the initial ADHD medication decreased over time of
follow-up, and this pattern was not different between the
three time cohorts. After 3 months, around two-thirds of
patients were still using the original ADHD drug, but at
1 year this proportion had dropped just under 40%. In
contrast, continuation of any ADHD drug treatment
increased from time cohort I to time cohort III with at each
measurement point (3, 6, 12 months after initiation) a rel-
ative increase in the continuation of 30–40%. The inci-
dence of discontinuation of any ADHD drug was lower in
the later time cohorts due to increased switching to and
addition of the newer ADHD drugs. In time cohort III, 25%
of patients had an alteration of their initial treatment: in
Table 1 Characteristics of incident users of ADHD drugs during 2002–2005 (N = 13,489)
Characteristics Time cohort I
Jan 2002–Dec 2002
Time cohort II
Jan 2003–June 2004
Time cohort III
July 2004–Dec 2005
Overall 2002–2005
N = 1,849 (13.7%) N = 5,555 (41.2%) N = 6,085 (45.1%) N = 13,489 (100%)
N % N % N % N %
Sex
Male 1,288 69.7 4,089 73.6 4,412 72.5 9,789 72.6
Female 561 30.3 1,466 26.4 1,673 27.5 3,700 27.4
Age
0–5 years 95 5.1 199 3.6 256 4.2 550 4.1
6–11 years 710 38.4 2,489 44.8 2,767 45.5 5,966 44.2
12–17 years 396 21.4 988 17.8 1,126 18.5 2,510 18.6
18–45 years 648 35.0 1,879 33.8 1,936 31.8 4,463 33.1
Type of initial ADHD drug
MPH IR 1,849 100 5,372 96.7 5,420 89.1 12,641 93.7
MPH ER NA NA 183 3.3 549 9.0 732 5.4
ATX NA NA NA NA 116 1.9 116 0.9
NA not available at that time
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12316.5%, the medication was switched, and in almost 9%,
another ADHD drug was added to the initially prescribed
drug. Overall, 90% of the switchers comprised MPH IR
users, of whom almost 94% switched to MPH ER and 6%
switched to ATX. Of the patients having an addition, 83%
were MPH IR users and most of them were added MPH ER
(data not shown).
Table 2 shows that the proportion of patients of dis-
continuing of ADHD drug users was higher among females
(72.0%) than among men (60.3%), yielding an adjusted HR
of 1.09 (95% CI 1.04–1.15) and among adults [18 years
(adjusted HR 1.13, 95% CI: 1.06–1.19 vs. 12–17 year olds)
in this particular study period. The inﬂuence of the deter-
minants did not differ between the three time cohorts.
Discussion
First, this study showed that the discontinuation rate of
treatment with ADHD drugs is high in all three time
cohorts after 3, 6 and 12 months, especially among women
and adults. Second, over time the discontinuation rate of
any ADHD drug use decreased because of increased
switching and addition following the availability of the
newer ADHD drugs MPH ER and ATX.
The discontinuation frequency in our study is within the
same range as found in other studies. Between 36 and 51%
of the children discontinued their ADHD medication
within 1 year after start (Bussing et al. 2005; Winterstein
et al. 2008). Only half of the children received their ADHD
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Fig. 1 Percentage of incident users having encountered one of the outcome events at 3, 6 and 12 months for the three time cohorts I, II, III. Time
cohort I January 2002–December 2002, time cohort II January 2003–June 2004, time cohort III July 2004–December 2005
Table 2 Risk of ADHD
treatment discontinuation
during total follow-up
(N = 13,489)
a Adjusted for other
characteristics in Table 2
Characteristics Number % Discontinued Crude HR (95% CI) Adjusted HR (95% CI)
a
Time cohort
Jan 2002–Dec 2002 1,458 78.9 1.00 (reference) 1.00 (reference)
Jan 2003–June 2004 3,864 69.6 0.86 (0.81–0.91) 0.98 (0.92–1.04)
July 2004–Dec 2005 3,248 53.4 0.70 (0.66–0.75) 0.86 (0.81–0.92)
Sex
Male 5,907 60.3 1.00 (reference) 1.00 (reference)
Female 2,663 72.0 1.39 (1.32–1.45) 1.09 (1.04–1.15)
Age category
0–5 years 294 53.5 0.64 (0.57–0.72) 0.67 (0.59–0.75)
6–11 years 2,910 48.8 0.52 (0.49–0.56) 0.53 (0.50–0.56)
12–17 years 1,810 72.1 1.00 (reference) 1.00 (reference)
18–45 years 3,556 79.7 1.37 (1.29–1.45) 1.13 (1.06–1.19)
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123medication for less than 3 years (Prosser and Reid 2009).
On the other hand, 77% of the parents of children
(6–18 years) diagnosed with ADHD reported in an online
questionnaire that the length of treatment was more than
1 year (Coghill et al. 2008). In the Netherlands, a retro-
spective study of patients aged 6–21 years in an outpatient
clinic for child and adolescent psychiatry showed that less
than 10% discontinued their medication and half of the
patients switched at least once between 2005 and 2006
(Pauw et al. 2008). Studies in adults also report high dis-
continuation rates. Only 24% of the patients initiated on
methylphenidate were still on treatment after 7 months
(Capone and McDonnel 2006). About 20% of the adult
ADHD patients in Norway still used their medication after
2 years between 1997 and 2003 (Aanonsen et al. 2004).
In our study, risk of discontinuation was higher among
females. This ﬁnding is in contrast with results from Faber
et al. (2005), who found no difference in duration of
stimulant use between boys and girls, but supports data
from Trip et al. (2009), who found that boys tended to use
their ADHD medication longer than girls. A recent Aus-
tralian study (Prosser and Reid 2009) found a decline in the
duration of treatment with ADHD drugs from 2.5 years in
1990–2000 to 2 years in 2000–2006 with no difference
between boys and girls aged less than 18 years. Their
ﬁnding is consistent with studies by Reid et al. (2002) and
Barbaresi et al. (2006). Differences in outcome of discon-
tinuation rates can be caused by study design, inclusion of
different ages, the prescriber, the treatment setting, the
motivation of patient and parents, duration of follow-up
and as in our study the introduction of newer ADHD drugs.
In time cohort III, after the introduction of MPH ER and
ATX, 16.5% of the incident ADHD drug users switched
their medication, mainly MPH IR to ER and almost 9%, of
whom 17% was adult, added an ADHD drug to the prior
ADHD drug, mainly MPH ER to IR. This is consistent with
the study of Pauw et al (2008) in which eighty per cent
switched from MPH IR to ER. Our hypothesis is that
switching from MPH IR to ER is associated with a greater
continuity of treatment than MPH IR. This is conﬁrmed in
studies in youth (Marcus et al. 2005; Lage and Hwang
2004) and adults (Olfson et al. 2007). Switching to the non-
stimulant drug ATX is probably because of side effects or
too little effect of MPH IR.
There are several studies on pharmacological mono-
therapy versus combined therapy for ADHD in youth.
Combined use of methylphenidate IR, ER or atomoxetine
has not been the main subject of a study, although some
data are available. Only 7% of the Australian children,
3–17 years old, received a combination of MPH IR and ER
in 2004 (Preen et al. 2007). Less than 2% of the children
between 2006 and 2008 used more than one psychostim-
ulant (Thompson et al. 2009). In adults, combined use of
ADHD drugs was determined in 19.7% of initial ato-
moxetine users, in 21.0% of initial extended-release stim-
ulant users and in 23.1% of the initial immediate-release
stimulant users between July 2003 and June 2004 (Pohl
et al. 2009). Hyperactivity predicted the combined use of
ADHD medication in adults initiated on atomoxetine.
As if ADHD can be seen as a lifetime disorder, it should
need chronic treatment. Medication is one of the most
powerful treatment options in ADHD (Faraone et al. 2006).
The high discontinuation rate in our study may reﬂect
suboptimal treatment for ADHD. Untreated ADHD is a
risk factor for trafﬁc accidents, emergency room visits,
school, work and marital problems, substance abuse and
psychopathology (Fischer et al. 1990; Barkley et al. 1993,
1996; Mannuzza et al. 1993; DiScala et al.1998; Leibson
et al. 2001; Wilens 2004; Sobanski et al. 2008a, b). Prob-
ably with the introduction of long-acting ADHD medica-
tion continuation of treatment can be optimized. In children
(6–17 year) and adults, initial use of MPH ER was asso-
ciated with a longer duration of treatment compared to the
initial use of MPH IR (Lage and Hwang 2004; Marcus
et al. 2005; Olfson et al. 2007). There are indications that
patients with more severe ADHD symptoms switch more
rapidly to long-acting drugs (Gau et al. 2008). There are
several reasons for discontinuation. Psychostimulants can
have a rapid effect on ADHD symptoms, and ADHD drug
users can think that they are cured by the medication and
stop. They can suffer from side effects or they disbelieve in
the effects of medication. The type of prescriber or setting
can inﬂuence their compliance. Probably, the ADHD drug
user did not suffer from ADHD or other treatment oppor-
tunities were available and effective in reducing the ADHD
symptoms.
Strengths of this study were that it was population based
and involved a large sample of persons using ADHD
medication. There are several limitations. We had no
information on the indication for which ADHD drugs were
prescribed. Although methylphenidate is the ﬁrst-choice
pharmacotherapeutical intervention in the treatment of
ADHD for children, adolescents (Practice Parameter for the
use of stimulant medications in the treatment of children,
adolescents and adults 2002; Multidisciplinaire Richtlijn
ADHD 2005) and adults (Kooij 2003; Spencer et al. 2005),
it can also be prescribed to adults for somatic problems
(Donker et al. 2005; Gagnon et al. 2005). Furthermore,
persistence of ADHD treatment might have been affected
by the prescriber, treatment setting or high costs of long-
acting medication, which are not always covered by health
insurance companies. Little is known about the inﬂuence of
studies or guidelines on ADHD drug treatment published in
professional journals (inter)national conventions or mar-
keting strategies of pharmaceutical companies on the pre-
scribing behaviour of health care professionals or the
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123perception on ADHD symptoms and medication of patients,
parents or teachers (Layton et al. 2008). These factors may
contribute to a more or less tolerant attitude towards ADHD
drugs. The Dutch clinical guideline was presented just
before the introduction of atomoxetine in the Netherlands
and could have inﬂuenced prescription behaviour.
In conclusion, discontinuation of ADHD drugs use is
high within 1 year after initiation. It decreased over cal-
endar time since the availability of long-acting ADHD
drugs, which make it possible to switch or use more than
one ADHD drug at the same time. Combined ADHD drug
therapy is not very common in the Netherlands. More
research on continuation, discontinuation, switching and
addition must be performed after 2006 to investigate
whether prescription of long-acting drugs further decreases
the rate of discontinuation. Backgrounds of switching to
MPH ER or ATX and effects of discontinuation of ADHD
drugs on school performance, comorbidity, marital and
family stress should be subject of future research.
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